参考文献/References:
[1] WANG T J C,MEHTA M P.Low-grade glioma radiotherapy treatment and trials[J].Neurosurg Clin N Am,2019,30(1):111-118.
[2] JIAPAER S,FURUTA T,TANAKA S,et al.Potential strategies overcoming the temozolomide resistance for glioblastoma[J].Neurol Med Chir (Tokyo),2018,58(10):405-421.
[3] 余露山,曾苏.基于表观遗传的摄取型药物转运体表达调控是肿瘤耐药干预的新途径[J].医学研究生学报,2019,32(5):449-454.
YU L S,ZENG S.Epigenetics-based regulation of uptake drug transporter expression is a new approach for cancer drug resistance intervention[J].J Med Postgra,2019,32(5):449-454.
[4] RAO A M,QUDDUSI A,SHAMIM M S.The significance of MGMT methylation in glioblastoma multiforme prognosis[J].J Pak Med Assoc,2018,68(7):1137-1139.
[5] WANG H W,XU Z K,SONG Y,et al.Correlations of MGMT genetic polymorphisms with temozolomide resistance and prognosis of patients with malignant gliomas:a population-based study in China[J].Cancer Gene Ther,2017,24(5):215-220.
[6] 占传家,朱文珍,王承缘.2007年世界卫生组织对于中枢神经系统肿瘤的分类[J].放射学实践,2008,23(2):122-127.
ZHAN C J,ZHU W Z,WANG C Y.2007 WHO classification of tumors of the central nervous system [J].Radiol Pract,2008,23(2):122-127.
[7] 吕爽,张海波,徐莹,等.复发脑胶质瘤再程放疗的远期疗效分析[J].中华放射肿瘤学杂志,2020,29(6):411-415.
LYU S,ZHANG H B,XU Y,et al.Analysis of long-term efficacy of re-irradiation for recurrent glioma[J].Chin J Radiat Oncol,2020,29(6):411-415.
[8] NABORS L B,PORTNOW J,AMMIRATI M,et al.NCCN guidelines insights:central nervous system cancers,version 1.2017[J].J Natl Compr Canc Netw,2017,15(11):1331-1345.
[9] MIYAUCHI J T,TSIRKA S E.Advances in immunotherapeutic research for glioma therapy[J].J Neurol,2018,265(4):741-756.
[10] MA R M,ZHENG G H,SHAO C Q,et al.Downregulation of miR-196b promotes glioma cell sensitivity to temozolomide chemotherapy and radiotherapy[J].Ann Clin Lab Sci,2018,48(6):719-725.
[11] BELL E H,ZHANG P,FISHER B J,et al.Association of MGMT promoter methylation status with survival outcomes in patients with high-risk glioma treated with radiotherapy and temozolomide:an analysis from the NRG oncology/RTOG 0424 trial[J].JAMA Oncol,2018,4(10):1405-1409.
[12] SIGNORELL R D,PAPACHRISTODOULOU A,XIAO J W,et al.Preparation of PEGylated liposomes incorporating lipophilic lomeguatrib derivatives for the sensitization of chemo-resistant gliomas[J].Int J Pharm,2018,536(1):388-396.
[13] 陈鑫,张国琴,阮秀杭,等.基于表观扩散系数直方图分析预测多形性胶质母细胞瘤MGMT基因启动子甲基化状态[J].实用放射学杂志,2020,36(6):965-968.
CHEN X,ZHANG G Q,RUAN X H,et al.ADC-based histogram analysis for prediction of MGMT gene promoter methylation status in glioblastoma multiform[J].J Pract Radiol,2020,36(6):965-968.
[14] 薛智文,王晓叶,魏益群.MGMT基因启动子甲基化与非小细胞肺癌化疗敏感性及预后的关系[J].海南医学院学报,2019,25(14):1083-1086,1091.
XUE Z W,WANG X Y,WEI Y Q.Relationship between methylation of MGMT gene promoter and chemosensitivity and prognosis of non-small cell lung cancer[J].J Hainan Med Univ,2019,25(14):1083-1086,1091.
[15] BINABAJ M M,BAHRAMI A,SHAHIDSALES S,et al.The prognostic value of MGMT promoter methylation in glioblastoma:a meta-analysis of clinical trials[J].J Cell Physiol,2018,233(1):378-386.
[16] O′REGAN C J,KEARNEY H,BEAUSANG A,et al.Temporal stability of MGMT promoter methylation in glioblastoma patients undergoing STUPP protocol[J].J Neurooncol,2018,137(2):233-240.
相似文献/References:
[1]刘晓斌,李 民,黄卫东.血清肿瘤坏死因子-α和胶质纤维酸性蛋白水平与脑胶质瘤恶性程度及患者预后的相关性[J].新乡医学院学报,2017,34(12):1097.[doi:10.7683/xxyxyxb.2017.12.013]
LIU Xiao-bin,LI Min,HUANG Wei-dong.Correlation between the levels of serum tumor necrosis factor-α,glial fibrillary acidic protein and the malignant degree and prognosis of patients with brain glioma[J].Journal of Xinxiang Medical University,2017,34(3):1097.[doi:10.7683/xxyxyxb.2017.12.013]
[2]李国林,李 超,李 峰.OBFC1基因多态性与脑胶质瘤患病风险的相关性[J].新乡医学院学报,2018,35(4):289.[doi:10.7683/xxyxyxb.2018.04.008]
LI Guo-lin,LI Chao,LI Feng.Correlation of OBFC1 gene polymorphism with the risk of glioma[J].Journal of Xinxiang Medical University,2018,35(3):289.[doi:10.7683/xxyxyxb.2018.04.008]